No Data
Jinling Pharmaceutical (000919.SZ): Currently collaborating on technical Business with Nanjing University, China Pharmaceutical University, and other institutions.
On January 6th, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) indicated in their investor interaction platform that the company is currently collaborating with Nanjing University, China Pharmaceutical University, and other institutions on technology and business.
Jinling Pharmaceutical (000919.SZ): No related technology or research on Brain-computer Interface.
On December 26, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company has no Brain-computer Interface related technology or research.
Market Is Not Liking Jinling Pharmaceutical's (SZSE:000919) Earnings Decline as Stock Retreats 11% This Week
Jinling Pharmaceutical (000919.SZ): Magnesium sulfate injection has been approved for registration.
On December 11, 2023, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a "Pharmaceutical Registration Certificate" for magnesium sulfate injection issued by the National Medical Products Administration (Notification Number: 2024S30151). Magnesium sulfate injection can be used as an anticonvulsant for pregnancy-induced hypertension, to lower blood pressure, and to treat preeclampsia and eclampsia. Magnesium sulfate plays an important role in the prevention and treatment of eclampsia, hypertensive crises, asthma, and other diseases. Currently, China's "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)" ...
Jinling Pharmaceutical Completes Cancellation of Subsidiary
Jinling Pharmaceutical: Report for the third quarter of 2024
Investors One-year Losses Continue as Jinling Pharmaceutical (SZSE:000919) Dips a Further 10% This Week, Earnings Continue to Decline
